var data={"title":"Lidocaine and prilocaine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lidocaine and prilocaine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6464?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lidocaine-and-prilocaine-drug-information\" class=\"drug drug_general\">see &quot;Lidocaine and prilocaine: Drug information&quot;</a> and <a href=\"topic.htm?path=lidocaine-and-prilocaine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lidocaine and prilocaine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188755\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>AgonEaze;</li>\n      <li>Anodyne LPT;</li>\n      <li>DermacinRx Empricaine;</li>\n      <li>DermacinRx Prizopak;</li>\n      <li>Dolotranz;</li>\n      <li>EMLA [DSC];</li>\n      <li>Leva Set;</li>\n      <li>Lido BDK;</li>\n      <li>Lidopril;</li>\n      <li>Lidopril XR;</li>\n      <li>LiProZonePak;</li>\n      <li>Livixil Pak;</li>\n      <li>LP Lite Pak;</li>\n      <li>Medolor Pak;</li>\n      <li>Oraqix;</li>\n      <li>Prikaan;</li>\n      <li>Prikaan Lite;</li>\n      <li>Prilolid;</li>\n      <li>Priloxx LP;</li>\n      <li>Relador Pak;</li>\n      <li>Venipuncture CPI</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188756\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>EMLA;</li>\n      <li>Oraqix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048241\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Analgesic, Topical</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antipruritic, Topical</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Local Anesthetic, Topical</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443848\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Smaller areas of treatment recommended in younger or smaller patients or those with impaired elimination; decreasing the duration of application may decrease analgesic effect; however, maximum application duration times should not be exceeded.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Circumcision (major dermal procedure):</b> GA &ge;37 weeks: Topical cream: Apply 1 to 2 g to prepuce and cover with occlusive dressing for 60 to 90 minutes prior to procedure (Weise, 2005) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Topical local anesthetic (minor dermal procedures [eg, IM injection, IV access, venipuncture]): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GA &lt;37 weeks: Limited data available: Topical: 0.5 g per site has been most frequently reported (Weise, 2005). One study of 30 preterm neonates (GA: &ge;30 weeks) showed application to the heel for 1 hour resulted in no measurable changes in methemoglobin levels; others have reported similar findings; monitor patients closely with use (Taddio, 1995; Weise, 2005) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GA &ge;37 weeks and weighing &lt;5 kg: Topical cream: Apply up to 1 g per site (typically 10 cm<sup>2</sup> area) cover with an occlusive dressing \tfor usual duration of application of 60 minutes prior to procedure; maximum total dose (for all sites combined): 1 g;  maximum application area: 10 cm<sup>2</sup>; maximum application time: 1 hour </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048234\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=lidocaine-and-prilocaine-drug-information\" class=\"drug drug_general\">see &quot;Lidocaine and prilocaine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Smaller areas of treatment recommended in smaller or debilitated patients or patients with impaired elimination; decreasing the duration of application may decrease analgesic effect, however maximum application duration times should not be exceeded.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Minor dermal procedures (eg, intravenous access, venipuncture, intramuscular injection); anesthetic:</b> Topical cream: General dosing information provided, dose should be individualized based on procedure and area to be anesthetized. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: Dosing based on patient weight:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;5 kg  Topical cream: Apply up to 1 g per 10 cm<sup>2</sup> area cover with an occlusive dressing for usual duration of application of 60 minutes prior to procedure. Maximum dosing information for a 24-hour period:  Maximum total dose (for all sites combined): 1 g; maximum application area: 10 cm<sup>2</sup>; maximum application time: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;5 kg to &le;10 kg: Topical cream: Apply 1 to 2 g per 10 cm<sup>2</sup> area; cover with occlusive dressing for at least 60 minutes,; maximum dosing information for a 24-hour period:  Maximum total dose (for all sites combined): 2 g; maximum application area: 20 cm<sup>2</sup>; maximum application time: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;10 kg to &le; 20 kg: Topical cream: Apply 1 to 2 g per 10 cm<sup>2</sup> area; cover with occlusive dressing for at least 60 minutes; maximum dosing information for a 24-hour period: Maximum total dose (for all sites combined): 10 g; maximum application area: 100 cm<sup>2</sup>; maximum application time: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;20 kg: Topical cream: Apply 1 to 2 g per 10 cm<sup>2</sup> area; cover with occlusive dressing for at least 60 minutes; maximum dosing information for a 24-hour period: Maximum total dose (for all sites combined): 20 g; maximum application area: 200 cm<sup>2</sup>; maximum application time: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Apply 2.5 g of cream (<sup>1</sup>/<sub>2</sub> of the 5 g tube) over 20 to 25 cm<sup>2</sup> of skin surface area for at least 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Major dermal procedures (eg, more painful dermatological procedures involving a larger skin area such as split thickness skin graft harvesting); anesthetic: </b> Topical cream: Adolescents: Apply 2 g of cream per 10 cm<sup>2</sup> of skin and allow to remain in contact with the skin for at least 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Male genital skin (eg, pretreatment prior to local anesthetic infiltration):</i> Apply a thick layer of cream (1 g/10 cm<sup>2</sup>) to the skin surface for 15 minutes. Local anesthetic infiltration should be performed immediately after removal of cream. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Female genital mucous membranes:</i> Minor procedures (eg, removal of condylomata acuminata, pretreatment for local anesthetic infiltration): Apply 5 to 10 g (thick layer) of cream for 5 to 10 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anesthetic:</b> Topical cream: Apply a thick layer to intact skin and cover with an occlusive dressing; <b>Note:</b> Dermal analgesia can be expected to increase for up to 3 hours under occlusive dressing and persist for 1-2 hours after removal of the cream.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Minor dermal procedures (eg, IV cannulation or venipuncture):</b> Topical cream: Apply 2.5 g of cream (<sup>1</sup>/<sub>2</sub>of the 5 g tube) over 20-25 cm<sup>2</sup> of skin surface area for at least 1 hour.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Major dermal procedures (eg, more painful dermatological procedures involving a larger skin area such as split thickness skin graft harvesting):</b> Topical cream: Apply 2 g of cream per 10 cm<sup>2</sup> of skin and allow to remain in contact with the skin for at least 2 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Adult male genital skin (eg, pretreatment prior to local anesthetic infiltration):</i></b> Apply a thick layer of cream (1 g/10 cm<sup>2</sup>) to the skin surface for 15 minutes. Local anesthetic infiltration should be performed immediately after removal of cream.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Adult female genital mucous membranes:</i></b> Minor procedures (eg, removal of condylomata acuminata, pretreatment for local anesthetic infiltration): Apply 5-10 g (thick layer) of cream for 5-10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Periodontal gel (Oraqix&reg;):</b> Apply on gingival margin around selected teeth using the blunt-tipped applicator included in package. Wait 30 seconds, then fill the periodontal pockets using the blunt-tipped applicator until gel becomes visible at the gingival margin. Wait another 30 seconds before starting treatment. May reapply if anesthesia starts to wear off; maximum recommended dose per treatment session: 5 cartridges (8.5 g) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188738\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AgonEaze: Lidocaine 2.5% and prilocaine 2.5% (2 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Anodyne LPT: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">DermacinRx Empricaine: Lidocaine 2.5% and prilocaine 2.5% (1 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">DermacinRx Prizopak: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dolotranz: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with lidocaine gel 4%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">EMLA: Lidocaine 2.5% and prilocaine 2.5% (5 g [DSC], 30 g [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Leva Set: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lido BDK: Lidocaine 2.5% and prilocaine 2.5% (5 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lidopril: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lidopril XR: Lidocaine 2.5% and prilocaine 2.5% (2 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LiProZonePak: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Livixil Pak: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">LP Lite Pak: Lidocaine 2.5% and prilocaine 2.5% (2 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Medolor Pak: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prikaan: Lidocaine 2.5% and Prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prikaan Lite: Lidocaine 2.5% and Prilocaine 2.5% (1 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prilolid: Lidocaine 2.5% and prilocaine 2.5% (1 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Priloxx LP: Lidocaine 2.5% and prilocaine 2.5%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Relador Pak: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Venipuncture CPI: Lidocaine 2.5% and prilocaine 2.5% (5 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: Lidocaine 2.5% and prilocaine 2.5% (5 g, 30 g, 5800 g, 18,000 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel, periodontal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oraqix: Lidocaine 2.5% and prilocaine 2.5% (1.7 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188725\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes: Cream</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048244\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream: For external use only. Avoid application to open wounds or near the eyes. Avoid use in situations where penetration or migration past the tympanic membrane into the middle ear is possible. In small infants and children, observe patient to prevent accidental ingestion of cream or dressing. To obtain 1 g of cream, squeeze narrow strip ~1.5 inches long and 0.2 inches wide from tube. Repeat as necessary to obtain quantity needed for dose (eg, 2 strips = 2 g dose). Apply a thick layer of cream to designated site of intact skin. Cover site with occlusive dressing. Mark the time on the dressing. Allow at least 1 hour (mild dermatologic procedures) or at least 2 hours (major dermal procedures) for optimum therapeutic effect. Remove the dressing and wipe off excess cream (gloves should be worn). Smaller areas of treatment are recommended for small children, debilitated patients, or patients with severe hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Periodontal gel: Oraqix is a viscous liquid: Make sure it is in the liquid form before administration; if semisolid gel forms, refrigerate until becomes liquid again. Do not use dental cartridge warmers; heat will cause product to gel prematurely (product is a microemulsion which is intended to form a gel in the periodental pocket). Apply slowly and evenly on gingival margin around selected teeth. Not to be used with standard dental syringes; use Oraqix Dispenser to apply.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188753\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i> Store between 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> Store between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patch (Canadian availability; not available in the US): Store between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Periodontal gel: Store at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F); do not freeze. May turn opaque at temperature of &le;5&deg;C. Do not use dental cartridge warmers; heat will cause product to gel prematurely (product is a microemulsion that is intended to form a gel in the periodontal pocket).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048243\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream: Topical anesthetic for use on normal intact skin to provide local analgesia for minor procedures such as IV cannulation or venipuncture; topical anesthetic for superficial minor surgery of genital mucous membranes and as an adjunct for local infiltration anesthesia in genital mucous membranes [FDA approved in neonates (full-term), pediatric, and adult patients]; has also been used for painful procedures, such as lumbar puncture and skin graft harvesting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Periodontal gel: Topical anesthetic for use in periodontal pockets during scaling or root planing procedures (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188778\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cream/patch:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Local alterations in temperature sensations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Hyperpigmentation, pallor (local), stinging of the skin (local), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Local purpuric or petechial reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Application site burning, application site edema, application site erythema, application site pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylactic shock, angioedema, blistering of foreskin, bronchospasm, central nervous system depression, central nervous system stimulation, central nervous system toxicity (high dose), circulatory shock (high dose), hypotension, methemoglobinemia (high dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Periodontal gel:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Bitter taste, fatigue</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Local hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Application site reaction (includes abscess, edema, irritation, numbness, pain, ulceration, vesicles)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Flu-like symptoms, respiratory tract infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188743\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to local anesthetics of the amide type or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Congenital or idiopathic methemoglobinemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Cream and patch only: Infants &le;12 months of age who require treatment with methemoglobin-inducing agents; preterm infants (gestational age &lt;37 weeks); procedures requiring large amounts over a large body area that are not conducted in a facility with health care professionals trained in the diagnosis and management of dose-related toxicity and other acute emergencies, and with appropriate resuscitative treatments and equipment. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188729\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Allergic and anaphylactic reactions may occur. Patients allergic to paraaminobenzoic acid derivatives (eg, procaine, tetracaine, benzocaine) have not shown cross sensitivity to lidocaine and/or prilocaine; use with caution in patients with a history of drug sensitivities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Methemoglobinemia: Has been reported in infants and children; associated with large doses, larger-than-recommended areas of application, neonates and infants &lt;3 months of age, and concomitant use of methemoglobinemia-inducing agents (eg, acetaminophen, benzocaine, chloroquine, dapsone, nitrofurantoin, nitroglycerin, nitroprusside, phenobarbital, phenytoin, quinine, sulfonamides). Neonates and infants up to 3 months of age should be monitored for methemoglobinemia. Do not use in preterm neonates (gestational age &lt;37 weeks), infants &lt;12 months of age requiring treatment with methemoglobinemia-inducing agents, or in patients with congenital or idiopathic methemoglobinemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Atopic dermatitis: Use with caution; rapid and greater absorption through the skin is observed in these patients; a shorter application time should be used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with severe impairment of impulse initiation and conduction in the heart (eg, grade II and III AV block, pronounced bradycardia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD may be more susceptible to drug-induced methemoglobinemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; risk of increased systemic exposure. Smaller treatment area may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acutely ill patients: Use with caution in acutely ill; smaller treatment area may be required consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Debilitated patients: Use with caution in debilitated patients; smaller treatment area may be required consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in elderly patients; smaller treatment area may be required consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage forms specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Periodontal gel: Do not use with standard dental syringes; only use with the supplied blunt-tipped applicator.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Although the incidence of systemic adverse reactions with use of the cream is very low, caution should be exercised, particularly when applying over large areas and leaving on for longer than 2 hours. When used prior to cosmetic or medical procedures, the smallest amount of cream necessary for pain relief should be applied. High systemic levels and toxic effects (eg, methemoglobinemia, irregular heartbeats, respiratory depression, seizures, death) have been reported in patients who (without supervision of a trained professional) have applied topical anesthetics in large amounts (or to large areas of the skin), left these products on for a prolonged time, or have used wraps/dressings to cover the skin following application. Do not apply to broken or inflamed skin, open wounds, or near the eyes. Avoid use in situations where penetration or migration past the tympanic membrane into the middle ear is possible; ototoxicity has been observed in animal studies. Avoid inadvertent trauma to the treated area (eg, scratching, rubbing, exposure to extreme hot or cold temperatures) until complete sensation has returned.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26022193\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Adjust dose in patients with increased risk for methemoglobinemia; use smaller areas for application in small children (especially infants &lt;3 months of age). In small infants and children, an occlusive bandage may prevent the child from placing the cream in his/her mouth or smearing the cream on the eyes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188768\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188733\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12553&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiarrhythmic Agents (Class III): Lidocaine (Topical) may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May increase the serum concentration of Lidocaine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of Bupivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with local anesthetics. Liposomal bupivacaine may be administered 20 minutes or more after the administration of lidocaine, but the optimal duration of dose separation for other local anesthetics is unknown<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: May enhance the arrhythmogenic effect of Lidocaine (Topical). Disopyramide may increase the serum concentration of Lidocaine (Topical). Specifically, the unbound/free fraction of lidocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188735\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188746\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with this combination. Lidocaine and prilocaine cross the placenta. Their use is not contraindicated during labor and delivery. Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25503644\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum methemoglobin before, during, and after use in neonates and infants up to 3 months of age</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188728\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Local anesthetic action occurs by stabilization of neuronal membranes and inhibiting the ionic fluxes required for the initiation and conduction of impulses</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188742\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Also see individual agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">EMLA: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Onset of action: 1 hour (more rapid in genital mucosa: 5 to 10 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Peak effect: 2 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Duration: 1 to 2 hours after removal; Genital mucosa: 15 to 20 minutes after application (range: 5 to 45 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Absorption: Related to duration of application and area where applied </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">3-hour application: 3.6% lidocaine and 6.1% prilocaine </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">24-hour application: 16.2% lidocaine and 33.5% prilocaine </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oraqix:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Onset of action: &le;30 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Duration: ~20 minutes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188745\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Lidocaine-Prilocaine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (5 g): $8.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (CadiraMD External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $259.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (DermacinRx Empricaine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,479.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (DermacinRx Prizopak External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,801.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Dolotranz External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5 &amp; 4% (1): $2,145.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Leva Set/Occlusive Dressing External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,200.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Lido BDK External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $249.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Lido-Prilo Caine Pack External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,885.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Lidocaine-Prilocaine External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $49.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (LiProZonePak External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,987.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Livixil Pak External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,660.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (LP Lite Pak External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $438.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Medolor Pak External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,771.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Prikaan External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,498.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Prikaan Lite External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $494.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Priloxx LP External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,986.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Relador Pak External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,651.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Relador Pak Plus External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $1,675.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Venipuncture CPI External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5-2.5% (1): $828.28</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188748\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anesteal (ES);</li>\n      <li>Anestecin crema (CO);</li>\n      <li>Anestesin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Anestil (EC);</li>\n      <li>Ansederm (FR);</li>\n      <li>Cainplus (LK);</li>\n      <li>Denela (ES, MT);</li>\n      <li>Dermacaine (TH);</li>\n      <li>Dolones (ID);</li>\n      <li>Duocaine (MY);</li>\n      <li>Emla (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CN, CY, CZ, DE, DK, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, ID, IE, IL, IQ, IR, IS, IT, JM, JO, JP, KE, KW, LB, LK, LR, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PL, PY, QA, RU, SA, SC, SD, SE, SI, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, VN, YE, ZA, ZM, ZW);</li>\n      <li>EMLA (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Emla Cream (NZ);</li>\n      <li>Emla Patch (NZ);</li>\n      <li>Emlocaine (PH);</li>\n      <li>Encain (HK);</li>\n      <li>Fortacin (IE);</li>\n      <li>Lidiprine (HK);</li>\n      <li>Liprido (TW);</li>\n      <li>Liprikaine (TH);</li>\n      <li>Lipril Cream (KR);</li>\n      <li>Lipro (MY);</li>\n      <li>Metacain DS (PH);</li>\n      <li>Oraqix (IE, SE);</li>\n      <li>Prila (QA);</li>\n      <li>Prilox (IN);</li>\n      <li>Racser (MY);</li>\n      <li>Skisia (BD);</li>\n      <li>Topsy (ID);</li>\n      <li>Xylocream (HK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Broadman LM, Soliman IE, Hannallah RS, et al, &ldquo;Analgesic Efficacy of Eutectic Mixture of Local Anesthetics (EMLA&reg;) vs Intradermal Infiltration Prior to Venous Cannulation in Children,&rdquo; <i>Am J Anaesth</i>, 1987, 34:S56. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carbajal R, Biran V, Lenclen R, et al, &quot;EMLA Cream and Nitrous Oxide to Alleviate Pain Induced by Palivizumab (Synagis) Intramuscular Injections in Infants and Young Children,&quot; <i>Pediatrics</i>, 2008, 121(6):e1591-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-prilocaine-pediatric-drug-information/abstract-text/18458035/pubmed\" target=\"_blank\" id=\"18458035\">18458035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EMLA Cream (lidocaine and prilocaine) [prescribing information]. Lake Forest, IL: Akorn; April 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halperin DL, Koren G, Attias D, et al, &ldquo;Topical Skin Anesthesia for Venous Subcutaneous Drug Reservoir and Lumbar Puncture in Children,&rdquo; <i>Pediatrics</i>, 1989, 84(2):281-4. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-prilocaine-pediatric-drug-information/abstract-text/2748256/pubmed\" target=\"_blank\" id=\"2748256\">2748256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaur G, Gupta P, and Kumar A, &quot;A Randomized Trial of Eutectic Mixture of Local Anesthetics During Lumbar Puncture in Newborns,&quot; <i>Arch Pediatr Adolesc Med</i>, 2003, 157(11):1065-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-prilocaine-pediatric-drug-information/abstract-text/14609894/pubmed\" target=\"_blank\" id=\"14609894\">14609894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robieux I, Kumar R, Radhakrishnan S, et al, &ldquo;Assessing Pain and Analgesia With a Lidocaine-Prilocaine Emulsion in Infants and Toddlers During Venipuncture,&rdquo; <i>J Pediatr</i>, 1991, 118(6):971-3. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-prilocaine-pediatric-drug-information/abstract-text/2040936/pubmed\" target=\"_blank\" id=\"2040936\">2040936</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taddio A, Shennan AT, Stevens B, et al, &ldquo;Safety of Lidocaine-Prilocaine Cream in the Treatment of Preterm Neonates,&rdquo; <i>J Pediatr</i>, 1995, 127(6):1002-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-prilocaine-pediatric-drug-information/abstract-text/8523173/pubmed\" target=\"_blank\" id=\"8523173\">8523173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weise KL and Nahata MC, &quot;EMLA for Painful Procedures in Infants,&quot; <i>J Pediatr Health Care</i>, 2005, 19(1):42-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lidocaine-and-prilocaine-pediatric-drug-information/abstract-text/15662361/pubmed\" target=\"_blank\" id=\"15662361\">15662361</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12553 Version 136.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F188755\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F188756\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048241\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443848\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048234\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F188738\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F188725\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048244\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F188753\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048243\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F188778\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F188743\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F188729\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26022193\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F188768\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F188733\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F188735\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F188746\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F25503644\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F188728\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F188742\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F188745\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F188748\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12553|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lidocaine-and-prilocaine-drug-information\" class=\"drug drug_general\">Lidocaine and prilocaine: Drug information</a></li><li><a href=\"topic.htm?path=lidocaine-and-prilocaine-patient-drug-information\" class=\"drug drug_patient\">Lidocaine and prilocaine: Patient drug information</a></li></ul></div></div>","javascript":null}